Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-08 01:08 | 2026-07-06 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Director, Officer | SELL | $36.12 | 4,800 | $173,376 | 84,040 |
| 2026-07-08 00:00 | 2026-07-06 | DMRA | Damora Therapeutics, Inc. | Winslow Garrett | Officer | OPT+S | $29.98 | 245 | $7,345 | 2,289 |
| 2026-07-07 23:50 | 2026-07-06 | NBP | NovaBridge Biosciences | Xu Cong Claire | Officer | OPT+S | $0.89 | 4,485 | $3,992 | 298,101 |
| 2026-07-07 23:00 | 2026-07-02 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Officer | OPT+S | $7.01 | 410 | $2,874 | 86,380 |
| 2026-07-07 23:02 | 2026-07-06 | IMNM | Immunome Inc. | Barchas Isaac | Director | SELL | $24.13 | 100,000 | $2,412,520 | 108,504 |
| 2026-07-07 22:29 | 2026-07-02 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% owner | SELL | $37.64 | 126,685 | $4,768,639 | 53,315 |
| 2026-07-07 22:04 | 2026-07-02 | KRRO | Korro Bio, Inc. | FORMELA JEAN FRANCOIS | Director | SELL | $14.02 | 110,023 | $1,542,974 | 146,305 |
| 2026-07-07 21:42 | 2026-07-02 | IMNM | Immunome Inc. | Lechleider Robert | Officer | OPT+S | $22.62 | 55,000 | $1,244,331 | 15,805 |
| 2026-07-07 21:00 | 2026-07-02 | BCYC | BICYCLE THERAPEUTICS PLC | Thompson Travis Alvin | Officer | SELL | $4.27 | 923 | $3,945 | 64,441 |
| 2026-07-07 21:00 | 2026-07-02 | BCYC | BICYCLE THERAPEUTICS PLC | Hannay Michael Charles Ferguson | Officer | SELL | $4.28 | 1,761 | $7,530 | 94,375 |
| 2026-07-07 21:00 | 2026-07-02 | BCYC | BICYCLE THERAPEUTICS PLC | Lee Kevin | Director, Officer | SELL | $4.28 | 7,642 | $32,701 | 603,671 |
| 2026-07-07 21:00 | 2026-07-02 | BCYC | BICYCLE THERAPEUTICS PLC | Skynner Michael | Officer | SELL | $4.28 | 2,391 | $10,231 | 157,171 |
| 2026-07-07 21:00 | 2026-07-02 | BCYC | BICYCLE THERAPEUTICS PLC | Perry Jennifer Scott | Officer | SELL | $4.29 | 1,412 | $6,054 | 91,052 |
| 2026-07-07 21:06 | 2026-07-07 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $86.62 | 3,500 | $303,170 | 153,902 |
| 2026-07-07 21:11 | 2026-07-06 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | Officer | SELL | $8.52 | 45,000 | $383,175 | 1,366,053 |
| 2026-07-07 20:47 | 2026-07-02 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | OPT+S | $45.16 | 21,082 | $952,050 | 519,227 |
| 2026-07-07 20:58 | 2026-07-06 | IMNN | Imunon, Inc. | Eylward Susan | Officer | SELL | $1.88 | 920 | $1,730 | 2,896 |
| 2026-07-07 20:30 | 2026-07-02 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Director | SELL | $40.00 | 3,000 | $120,000 | 19,225 |
| 2026-07-07 20:38 | 2026-07-06 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | Officer | OPT+S | $43.60 | 10,250 | $446,862 | 0 |
| 2026-07-07 20:15 | 2026-07-02 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $524.99 | 1,500 | $787,485 | 45,321 |
| 2026-07-07 20:23 | 2026-07-06 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $3.51 | 9,022 | $31,667 | 81,385 |
| 2026-07-07 20:23 | 2026-07-02 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $3.54 | 7,851 | $27,793 | 90,407 |
| 2026-07-07 20:05 | 2026-07-02 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | SELL | $650.15 | 200 | $130,030 | 17,303 |
| 2026-07-07 20:08 | 2026-07-02 | VRTX | VERTEX PHARMACEUTICALS INC / MA | McKechnie Duncan | Officer | SELL | $519.00 | 1,541 | $799,779 | 11,001 |
| 2026-07-07 13:10 | 2026-07-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $548.96 | 9,500 | $5,215,133 | 40,513 |
| 2026-07-06 20:30 | 2026-07-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $123.58 | 11,430 | $1,412,519 | 85,533 |
| 2026-07-06 20:13 | 2026-07-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer | SELL | $502.71 | 828 | $416,244 | 19,131 |
| 2026-07-06 20:30 | 2026-07-01 | ALXO | ALX ONCOLOGY HOLDINGS INC | Wong Shelly | Officer | SELL | $2.04 | 1,404 | $2,864 | 88,401 |
| 2026-07-06 20:14 | 2026-07-01 | ZLAB | Zai Lab Ltd | GAYNOR RICHARD | Director | BUY | $19.05 | 1,736 | $33,071 | 80,737 |
| 2026-07-06 20:10 | 2026-07-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $32.66 | 7,228 | $236,068 | 27,598 |
| 2026-07-07 01:40 | 2026-07-02 | ANIP | ANI PHARMACEUTICALS INC | CAREY STEPHEN P. | Officer | OPT+S | $86.00 | 3,313 | $284,918 | 177,543 |
| 2026-07-06 22:49 | 2026-07-01 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | OPT+S | $79.04 | 11,518 | $910,416 | 11,014 |
| 2026-07-06 22:23 | 2026-07-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $240.47 | 6,000 | $1,442,820 | 366,682 |
| 2026-07-06 21:43 | 2026-07-01 | BOLD | Boundless Bio, Inc. | ARCH Venture Fund IX, L.P. | 10% owner | OPT+S | $2.49 | 16,000 | $39,840 | 0 |
| 2026-07-06 21:44 | 2026-07-01 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $79.47 | 25,000 | $1,986,695 | 855,073 |
| 2026-07-06 21:44 | 2026-07-01 | BOLD | Boundless Bio, Inc. | CRANDELL KEITH | 10% owner | OPT+S | $2.49 | 16,000 | $39,840 | 0 |
| 2026-07-06 21:11 | 2026-07-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | OPT+S | $313.28 | 5,000 | $1,566,377 | 41,514 |
| 2026-07-06 20:44 | 2026-07-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $88.35 | 25,000 | $2,208,738 | 9,755 |
| 2026-07-06 20:48 | 2026-07-06 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer | SELL | $54.03 | 2,034 | $109,897 | 227,490 |
| 2026-07-06 20:31 | 2026-07-01 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $123.59 | 23,000 | $2,842,570 | 58,117 |
| 2026-07-06 19:37 | 2026-07-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $33.13 | 4,698 | $155,645 | 100,991 |
| 2026-07-02 20:40 | 2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | Officer | SELL | $8.03 | 90,000 | $722,511 | 1,691,126 |
| 2026-07-02 20:30 | 2026-06-30 | ABEO | ABEONA THERAPEUTICS INC. | Alland Leila | Director | SELL | $5.92 | 11,000 | $65,087 | 162,614 |
| 2026-07-02 20:10 | 2026-07-01 | MLTX | MoonLake Immunotherapeutics | Santos da Silva Jorge | Director, Officer | SELL | $20.03 | 47,775 | $956,933 | 2,877,118 |
| 2026-07-02 20:10 | 2026-07-01 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $55.88 | 9,099 | $508,454 | 0 |
| 2026-07-02 20:08 | 2026-06-30 | RPRX | Royalty Pharma plc | Hite Christopher | Officer | SELL | $56.50 | 130,000 | $7,345,468 | 40,000 |
| 2026-07-02 20:05 | 2026-06-30 | LEGN | Legend Biotech Corp | Casey Patrick John | Director | SELL | $14.80 | 6,000 | $88,800 | 48,604 |
| 2026-07-02 21:21 | 2026-07-01 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Director, Officer | OPT+S | $39.41 | 200,000 | $7,881,400 | 24,555 |
| 2026-07-02 20:38 | 2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $8.03 | 16,666 | $133,860 | 1,161,128 |
| 2026-07-02 20:59 | 2026-06-30 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | OPT+S | $46.42 | 30,000 | $1,392,600 | 148,235 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.